Tumor-infiltrating Lymphocytes as Markers of the Antitumor Therapy Efficacy: Myth or Reality?-Reference-Cited by-同舟云学术

Tumor-infiltrating Lymphocytes as Markers of the Antitumor Therapy Efficacy: Myth or Reality?

Published:2022 Issue: Volume: Page:
ISSN:2731-4561
Container-title:Interdisciplinary Cancer Research
language:
Short-container-title:

Author:

Kiselevskiy Mikhail V.^ORCID,Zabotina Tatiana N.^ORCID,Artamonova Elena V.^ORCID,Kozlov A. N.^ORCID,Samoylenko Igor V.^ORCID,Kadagidze Zaira G.^ORCID,Shubina Irina Zh.^ORCID

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/16833_2022_59

Reference92 articles.

1. Ahmadzadeh M, Felipe-Silva A, Heemskerk B et al (2008) FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanomalesions. Blood 112(13):4953–4960

2. Almangush A, Jouhi L, Atula T, Haglund C, Mäkitie AA, Hagström J, Leivo I (2022) Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the international immuno-oncology biomarker working group. Br J Cancer 126(11):1589–1594

3. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14:5220–5227

4. Bendall SC, Simonds EF, Qiu P, Amir EAD, Krutzik PO, Finck R et al (2011) Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332(6030):687–696

5. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on gynecologic oncology. Int J Gynaecol Obstet 70:209–262